MacroGenics, Inc. MacroGenics, Inc.

MacroGenics, Inc.

MGNX

Rank in Stocks #18059
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers,... MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The companyโ€™s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Share Price
$2.20
Last synced: 2026-11-13
Market Cap
$140.24M
Change (1 day)
-3.93%
Change (1 year)
60.58%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Category

Healthcare
EPS for MacroGenics, Inc. (MGNX)
EPS as of September 2026 TTM: $-0.81
According to MacroGenics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.81. At the end of 2025 the company had an EPS of $-1.18, a decrease compared to its 2024 EPS of $-1.07.
EPS history for MacroGenics, Inc. from 2011 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.81 -31.36%
2025 $-1.18 10.28%
2024 $-1.07 613.33%
2023 $-0.15 -92.31%
2022 $-1.95 -42.14%
2021 $-3.37 36.44%
2020 $-2.47 -21.84%
2019 $-3.16 -24.58%
2018 $-4.19 675.93%
2017 $-0.54 -68.05%
2016 $-1.69 168.25%
2015 $-0.63 -55.00%
2014 $-1.40 13,625.49%
2013 $-0.01 -102.22%
2012 $0.46 24.32%
2011 $0.37 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 9.88%
US
$15.66 -2,033.33%
US
$-7.07 772.84%
US
$-5.29 553.09%
AU
$12.73 -1,671.88%
BE

Questions about MacroGenics, Inc.'s earnings per share (EPS)

What is MacroGenics, Inc.'s earnings per share (EPS)?

MacroGenics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.81, as of Sep 2026.

What was MacroGenics, Inc.'s earnings per share (EPS) in 2025?

In 2025, MacroGenics, Inc.'s earnings per share (EPS) was $-1.18, compared with $-1.07 in 2024.

How has MacroGenics, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, MacroGenics, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.15) and lowest in 2021 ($-3.37).

How does MacroGenics, Inc.'s earnings per share (EPS) compare with similar companies?

MacroGenics, Inc.'s earnings per share (EPS) ($-0.81) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.